Pre-clinical studies using EGFRL858R/T790M-driven tumor models have shown that afatinib-cetuximab combination treatment can achieve significant tumor regression [17], a finding further confirmed in patients with acquired resistance to EGFR TKIs [18]. Here, EGFR is linked to neoplasm.